Occasional numbness or tingling rare, more common with CJC-1295 at higher doses
The Ministry of Health and Long-Term Care perspective was taken, and all costs are expressed in 2013 Canadian dollars
Most users report visible improvements starting around 8 to 12 weeks of consistent injectable use, with optimal results building over 12 or more weeks of continuous administration
and active bacterial, fungal, or viral infection over the face were excluded from the study
A randomised controlled trial published in Clinical Infectious Diseases demonstrated that Thymosin Alpha-1 treatment in severe COVID-19 patients reduced 28-day mortality by 30% compared to standard care alone.17 While this was acute disease, not long COVID, it confirms the biological plausibility of the immune mechanism
Two products, Enso Supergreens and A